PKMYT1 and chronic myelogenous leukemia, BCR-ABL1 positive: However, transitioning into the accelerated phase marks a turning point where tumor cells become more aggressive, accelerating cancer progression and posing a grave threat to patients' lives.[39] Our results demonstrated that knocking down PKMYT1 in cancer cells delayed CML onset in mice and significantly slowed cancer progression.